Daiichi Sankyo's Roteas Receives European Approval, Expanding its Presence in the DOAC Market
Regulatory Approval Achieved Through Duplicate Application
Daiichi Sankyo's Roteas (edoxaban), a direct factor Xa inhibitor, has received final approval from the European Medicines Agency (EMA). This approval was obtained through a duplicate application procedure, based on the same scientific data as the previously launched Lixiana. By reconfirming the safety and efficacy of Roteas, Daiichi Sankyo has established a commercial foundation to implement a multi-brand strategy in the European market. This strategic move aims to diversify the patent and trademark risks associated with a single product and maximize market penetration.
Demonstrated Excellent Bleeding Safety and Convenience
The primary indication for Roteas is the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism. The results of the Phase 3 ENGAGE AF-TIMI 48 study demonstrated superior bleeding safety and equivalent efficacy compared to warfarin, the existing standard treatment. In particular, Roteas offers greater convenience in dosage adjustments for patients with impaired renal function compared to other competing DOAC products such as apixaban and rivaroxaban, leading to higher prescription rates in clinical practice. This approval will provide healthcare professionals and patients with a broader range of anticoagulation treatment options.
Diversifying European Distribution Network Through Partnerships
Following the approval of Roteas, Daiichi Sankyo has diversified its distribution partnerships to maximize sales synergies in the European market. In December 2019, it decided to transfer the marketing and distribution rights for Roteas in Europe to Berlin-Chemie AG, a subsidiary of the Menarini Group. This allows Daiichi Sankyo to focus its marketing efforts on its existing product, Lixiana, while leveraging Berlin-Chemie's strong local sales network to simultaneously increase market share. This partnership represents a typical asset optimization strategy employed by venture capital firms and large pharmaceutical companies, aiming to generate royalty income from the transfer of rights and strengthen market dominance.
Global DOAC Market Outlook and Competitive Landscape
The global direct oral anticoagulant (DOAC) market is estimated to be worth approximately $20.4 billion to $42.5 billion by 2025, with a stable annual growth rate of 7-9%. Daiichi Sankyo's edoxaban-based sales reached 287.7 billion yen (approximately $1.85 billion) in fiscal year 2023, making it a key revenue driver for the company. In a market dominated by Eliquis (BMS and Pfizer) and Xarelto (Bayer), Roteas is a latecomer but is rapidly targeting niche markets through a differentiated partnership model. In the future, research and development efforts will continue to focus on expanding indications and maintaining the brand value of the original drug until the expected patent expiration in Europe around 2030, in order to extend the product lifecycle and maximize commercial value before the original patent expires.
The EMA's final approval of Roteas marks a significant step for Daiichi Sankyo, enabling it to expand its edoxaban franchise across the European DOAC market, which currently generates over 287.7 billion yen (approximately $1.85 billion) in annual revenue. By adding the duplicate-approved Roteas to its existing product, Lixiana, and transferring the marketing rights to Berlin-Chemie AG, a subsidiary of the Menarini Group, Daiichi Sankyo aims to rapidly expand its prescription market share in Europe through this partnership. In the medium to long term, this strategy will allow Daiichi Sankyo to extend the product lifecycle and maximize the commercial value of its original drug before patent expiration, enabling it to compete with leading DOACs such as Eliquis and Xarelto in the global DOAC market, which is projected to reach $42.5 billion by 2025. From a research and development perspective, this duplicate approval case serves as an excellent benchmark for utilizing European regulatory pathways to expedite market entry and optimize regulatory strategies.
Source: EMA (ema)